ArticleCurrent medical imaging2026
Feasibility of Ultra-Dilute Iodine Contrast Agent in Dual-Layer Spectral CT for Pulmonary Artery Imaging
Article in Current medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study aimed to investigate the clinical feasibility of using an ultra-dilute, low-concentration iodine contrast agent in combination with duallayer spectral computed tomography (CT) for pulmonary artery imaging.
methodsA total of 143 patients who underwent CT pulmonary angiography (CTPA) between May 2024 and May 2025 were enrolled. After excluding 19 patients with suboptimal image quality due to technical factors, 124 patients were included in the final analysis (spectral group: n = 64; control group: n = 60). Patients were assigned to either a spectral group (100 kV, 160 mgI/mL contrast, 25 mL, 2.5 mL/s) or a control group (120 kV, 350 mgI/mL contrast, 35 mL, 4 mL/s). In the spectral group, images were reconstructed using conventional CT and virtual monoenergetic imaging at 40, 70, and 110 keV. The control group underwent conventional CT imaging only. Image quality, CT attenuation values, signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR), and radiation doses were assessed and compared between the two groups.
resultsIn the spectral group, 40 keV monoenergetic images yielded the highest CT values, SNR, and CNR for all pulmonary artery branches. The control group demonstrated superior image quality on conventional CT and at higher monoenergetic levels (70 and 110 keV), with statistically significant differences (P < 0.05). However, no significant differences were observed between the 40 keV spectral images and the control group. Subjective image quality scores were significantly lower at 70 and 110 keV, but comparable at 40 keV (P > 0.05). DISCUSSION: The use of an ultra-low concentration iodine contrast agent (160 mgI/mL) combined with dual-layer spectral CT provides diagnostic image quality equivalent to that of conventional protocols, while reducing the iodine load by 67% (to 4 g per examination). This approach reduces iodine load while maintaining diagnostic image quality, although its effect on renal safety requires further clinical validation.
conclusionDual-layer spectral CT combined with 40 keV virtual monoenergetic imaging allowed pulmonary artery imaging with markedly reduced iodine load while maintaining diagnostic image quality comparable to that of the conventional protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.